Disparities in Provider Recommendation of Human Papillomavirus Vaccination for U.S. Adolescents

Journal of Adolescent Health

Volumn 59, Issue 5, 2016, Pages 592-598

  Mohammed, Kahee A ^a   Geneus, Christian J ^b   Osazuwa Peters, Nosayaba ^a,c,d   Adjei Boakye, Eric ^a   Tobo, Betelihem B ^c   Burroughs, Thomas E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

Author keywords

Adolescent; HPV vaccine; Human papillomavirus; NIS Teen; Provider; Recommendation

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; BLACK PERSON; CAUCASIAN; CROSS-SECTIONAL STUDY; DEMOGRAPHY; EDUCATIONAL STATUS; FEMALE; GROUPS BY AGE; HEALTH CARE DISPARITY; HIGH SCHOOL; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; POVERTY; PREVALENCE; PRIORITY JOURNAL; SECONDARY ANALYSIS; SOCIAL STATUS; UNITED STATES; VACCINATION; WART VIRUS; ATTITUDE TO HEALTH; CLINICAL PRACTICE; QUESTIONNAIRE; REGRESSION ANALYSIS; SEX FACTOR; SOCIAL CLASS; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTHCARE DISPARITIES; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE PATTERNS, PHYSICIANS'; REGRESSION ANALYSIS; SEX FACTORS; SOCIAL CLASS; SURVEYS AND QUESTIONNAIRES; UNITED STATES; VACCINATION;

EID: 84994850680     PISSN: 1054139X     EISSN: 18791972     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2016.06.005     Document Type: Article

References (40)

1. [1] Satterwhite, C.L., Torrone, E., Meites, E., et al. Sexually transmitted infections among US women and men: Prevalence and incidence estimates, 2008. Sex Transm Dis 40 (2013), 187–193.
2. [2] Chesson, H.W., Dunne, E.F., Hariri, S., et al. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41 (2014), 660–664.
3. [3] Ley, C., Bauer, H.M., Reingold, A., et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst 83 (1991), 997–1003.
4. [4] Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004-2008. MMWR Morb Mortal Wkly Rep 61 (2012), 258–261.
5. [5] Petrosky, E., Bocchini, J.A. Jr., Hariri, S., et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64 (2015), 300–304.
6. [6] Reagan-Steiner, S., Yankey, D., Jeyarajah, J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years–United States, 2014. MMWR Morb Mortal Wkly Rep 64 (2015), 784–792.
7. [7] U.S. Department of Health and Human Services. 2020 topics and objectives: immunization and infectious diseases objectives. Available at: http://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives?topicId=23. Accessed January 28, 2016.
8. [8] Reiter, P.L., Brewer, N.T., Gottlieb, S.L., et al. Parents' health beliefs and HPV vaccination of their adolescent daughters. Social Sci Med (1982) 69 (2009), 475–480.
9. [9] Ylitalo, K.R., Lee, H., Mehta, N.K., Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health 103 (2013), 164–169.
10. [10] Gilkey, M.B., Moss, J.L., McRee, A.L., et al. Do correlates of HPV vaccine initiation differ between adolescent boys and girls?. Vaccine 30 (2012), 5928–5934.
11. [11] Centers for Disease Control and Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morb Mortal Wkly Rep 62 (2013), 591–595.
12. [12] Stokley, S., Jeyarajah, J., Yankey, D., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014–United States. MMWR Morb Mortal Wkly Rep 63 (2014), 620–624.
13. [13] Daley, M.F., Crane, L.A., Markowitz, L.E., et al. Human papillomavirus vaccination practices: A survey of us physicians 18 months after licensure. Pediatrics 126 (2010), 425–433.
14. [14] Kessels, S.J., Marshall, H.S., Watson, M., et al. Factors associated with HPV vaccine uptake in teenage girls: A systematic review. Vaccine 30 (2012), 3546–3556.
15. [15] Laz, T.H., Rahman, M., Berenson, A.B., Human papillomavirus vaccine uptake among 9–17 year old males in the United States: The National Health Interview Survey, 2010. Hum Vaccines Immunotherapeutics 9 (2013), 874–878.
16. [16] Jain, N., Singleton, J.A., Montgomery, M., et al. Determining accurate vaccination coverage rates for adolescents: The national immunization survey-teen 2006. Public Health Rep (Washington, DC: 1974) 124 (2009), 642–651.
17. [17] U.S. Department of Health and Human Services (DHHS), National Center for Health Statistics. The 2014 National Immunization Survey - Teen. 2014, Centers for Disease Control and Prevention, Hyattsville, MD.
18. [18] Bruno, D.M., Wilson, T.E., Gany, F., et al. Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations. Vaccine 32 (2014), 4149–4154.
19. [19] Reiter, P.L., Brewer, N.T., Gilkey, M.B., et al. Early adoption of the human papillomavirus vaccine among Hispanic adolescent males in the United States. Cancer 120 (2014), 3200–3207.
20. [20] Kahn, J.A., Cooper, H.P., Vadaparampil, S.T., et al. Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: A statewide survey of Texas physicians. Cancer Epidemiol Biomarkers Prev 18 (2009), 2325–2332.
21. [21] Gilkey, M.B., Malo, T.L., Shah, P.D., et al. Quality of physician communication about human papillomavirus vaccine: Findings from a national survey. Cancer Epidemiol Biomarkers Prev 24 (2015), 1673–1679.
22. [22] Gilkey, M.B., McRee, A.L., Provider communication about HPV vaccination: A systematic review. Hum Vaccin Immunother 12 (2016), 1434–1468.
23. [23] Giuliano, A.R., Palefsky, J.M., Goldstone, S., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. New Engl J Med 364 (2011), 401–411.
24. [24] Kahn, J.A., Zimet, G.D., Bernstein, D.I., et al. Pediatricians' intention to administer human papillomavirus vaccine: The role of practice characteristics, knowledge, and attitudes. J Adolesc Health 37 (2005), 502–510.
25. [25] Markowitz, L.E., Dunne, E.F., Saraiya, M., et al. Quadrivalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 56 (2007), 1–24.
26. [26] Eaton, D.K., Kann, L., Kinchen, S., et al. Youth risk behavior surveillance—United States, 2009. MMWR Surveill Summ (Washington, DC: 2002) 59 (2010), 1–142.
27. [27] Cutts, F.T., Franceschi, S., Goldie, S., et al. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ 85 (2007), 719–726.
28. [28] Rand, C.M., Shone, L.P., Albertin, C., et al. National health care visit patterns of adolescents: Implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 161 (2007), 252–259.
29. [29] Markowitz, L.E., Dunne, E.F., Saraiya, M., et al. Human papillomavirus vaccination: Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recommen Rep 63 (2014), 1–30.
30. [30] Tsai, Y., Zhou, F., Wortley, P., et al. Trends and characteristics of preventive care visits among commercially insured adolescents, 2003-2010. J Pediatr 164 (2014), 625–630.
31. [31] LeBaron, C.W., Massoudi, M., Stevenson, J., et al. Vaccination coverage and physician distribution in the United States, 1997. Pediatrics, 107, 2001, E31.
32. [32] Rosenblatt, R.A., Hart, L.G., Physicians and rural America. West J Med 173 (2000), 348–351.
33. [33] Cunningham, P.J., State variation in primary care physician supply: Implications for health reform Medicaid expansions. Res Brief 19 (2011), 1–11.
34. [34] Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13-17 years–United States, 2012. MMWR Morb Mortal Wkly Rep 62 (2013), 685–693.
35. [35] Dorell, C.G., Yankey, D., Santibanez, T.A., et al. Human papillomavirus vaccination series initiation and completion, 2008-2009. Pediatrics 128 (2011), 830–839.
36. [36] Sambamoorthi, U., McAlpine, D.D., Racial, ethnic, socioeconomic, and access disparities in the use of preventive services among women. Prev Med 37 (2003), 475–484.
37. [37] Agency for Healthcare Research and Quality 2014 National Healthcare Quality & Disparities Report. Available at: http://www.ahrq.gov/research/findings/nhqrdr/nhqdr14/index.html. Accessed February 7, 2016.
38. [38] Malo, T.L., Ali, K.N., Sutton, S.K., et al. The content and context of physicians' communication with males about human papillomavirus vaccination. Hum Vaccin Immunother 12 (2016), 1511–1518.
39. [39] Greenfield, L.S., Page, L.C., Kay, M., et al. Strategies for increasing adolescent immunizations in diverse ethnic communities. J Adolesc Health 56 (2015), S47–S53.
40. [40] Vadaparampil, S.T., Kahn, J.A., Salmon, D., et al. Missed clinical opportunities: Provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine 29 (2011), 8634–8641.